ライフサイエンスコーパス: HTLV-1

1 HTLV-1 and HTLV-2 encode auxiliary proteins that play im

2 HTLV-1 cell-to-cell transmission is dependent on the rel

3 HTLV-1 clonality studies revealed the presence of multip

4 HTLV-1 encodes a protein from the antisense strand of it

5 HTLV-1 infection can lead to many different and often fa

6 HTLV-1 infection is endemic to Central African populatio

7 HTLV-1 infection is the etiological agent of ATL and, un

8 HTLV-1 is a complex retrovirus that causes two distinct

9 HTLV-1 is now known to infect at least 4-10 million peop

10 HTLV-1 orf-I encodes two proteins, p8 and p12, whose fun

11 HTLV-1 prevalence was 8.6% (23/269) in individuals with

12 HTLV-1 prevalences for children and adults were 6.1% and

13 HTLV-1 primarily infects T cells and initially spreads w

14 HTLV-1 protease (HTLV-1 PR) is an aspartic protease whic

15 HTLV-1 serology was performed by Western blot on plasma

16 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lym

17 ss the infectivity of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/SCID/gam

18 e of human T-cell lymphotropic virus type 1 (HTLV-1) and hepatitis B virus (HBV) coinfection is high

19 such as human T-cell leukemia virus type 1 (HTLV-1) and HIV-1.

20 Human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 encode auxiliary proteins that play i

21 s of human T-cell lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1),

22 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

23 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

24 against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could b

25 PORTANCE Human T-cell leukemia virus type 1 (HTLV-1) causes a variety of diseases, ranging from a fat

26 Human T-lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukemia, a disease commonly

27 Human T-cell leukemia virus type 1 (HTLV-1) causes multiple pathological effects, ranging fr

28 trovirus human T-cell leukemia virus type 1 (HTLV-1) contains identical DNA sequences, known as long

29 Human T-cell leukemia virus type 1 (HTLV-1) expression depends on the concerted action of Ta

30 ssion, of human T lymphotropic virus type 1 (HTLV-1) expression, while YY1 down-regulation reduces HT

31 ple, human T-cell lymphotropic virus type 1 (HTLV-1) has been reported to infect up to 25 million peo

32 from Human T-cell Lymphotropic Virus Type 1 (HTLV-1) infection to lethal Adult T-cell Leukaemia (ATL)

33 Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus and the most oncogenic path

34 Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus, and, as such, its genome become

35 Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that induces a fatal

36 ith human T-cell lymphotrophic virus type 1 (HTLV-1) is associated with shorter survival for adults a

37 cture of human T-cell leukemia virus type 1 (HTLV-1) is poorly characterized.

38 Human T-cell lymphotropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tro

39 Human T cell leukemia virus type 1 (HTLV-1) is the ethological agent of adult T cell leukemi

40 Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemi

41 that the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax induces an epigenetic-dependent

42 able for human T-cell leukemia virus type 1 (HTLV-1) particle biogenesis.

43 Human T-cell leukemia virus type 1 (HTLV-1) propagates within and between individuals via ce

44 Human T cell leukemia virus, type 1 (HTLV-1) replication and spread are controlled by differe

45 The human T-cell leukaemia virus type 1 (HTLV-1) subtype c is endemic to central Australia.

46 ected by human T-cell leukemia virus type 1 (HTLV-1) that recapitulate adult T-cell leukemia (ATL)-li

47 cted with Human T Lymphotropic Virus type 1 (HTLV-1) which together with existing data allows us to s

48 Human T cell leukemia virus type 1 (HTLV-1), also known as human T lymphotropic virus type 1

49 Tax from human T-cell leukemia virus type 1 (HTLV-1), an etiological factor that causes adult T-cell

50 Human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia and T-cell lymp

51 Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is an inflammatory c

52 Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

53 in a human T-cell lymphotropic virus type 1 (HTLV-1)-endemic area of Central Australia, and report on

54 and human T-cell lymphotropic virus type 1 (HTLV-1)-infected cells with 2-10 muM P27 caused cell mem

55 en in 22 human T cell leukemia virus type 1 (HTLV-1)-infected individuals by assessing their infectiv

56 0 million human T-lymphotropic virus type 1 (HTLV-1)-infected people, and many of them will develop s

57 aused by human T-cell leukemia virus type 1 (HTLV-1).

58 h is human T-cell lymphotropic virus type 1 (HTLV-1).

59 and human T cell lymphotropic virus type 1 (HTLV-1).

60 SHV), and human T-lymphotropic virus type 1 (HTLV-1).

61 trovirus human T-cell leukemia virus type 1 (HTLV-1).

62 Human T-lymphotropic virus type-1 (HTLV-1) persists within hosts via infectious spread (de

63 aused by human T-cell leukemia virus type-1 (HTLV-1).

64 trovirus human T-cell leukemia virus type-1 (HTLV-1).

65 -kappaB by the human T-lymphotropic virus 1 (HTLV-1) oncoprotein Tax immediately triggers a host sene

66 ies, including human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

67 like the distantly related lentivirus HIV-1, HTLV-1 causes disease in only 5-10% of infected people,

68 everal regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene constitu

69 a panel of Gag proteins with chimeric HIV-1/HTLV-1 CA domains.

70 ously thought (typically between 104 and 105 HTLV-1+ T cell clones in the body of an asymptomatic car

71 Five subjects with HAM and 2 HTLV-1 asymptomatic carriers were studied.

72 uman T cell lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2) and bovine leukaemia virus (BLV).

73 Human T-lymphotropic viruses type 1 and 2 (HTLV-1/2) are prevalent in endemic clusters globally, an

74 The 23 HTLV-1-positive bitten individuals reported being bitten

75 Mother-to-child infection was excluded in 6 HTLV-1-infected bitten individuals.

76 (C. agilis in one case) were infected with a HTLV-1 subtype F strain very similar to the STLV-1 strai

77 ersists during chronic infection, even after HTLV-1 proviral load has reached its set point, and we e

78 d retained robust oncolytic activity against HTLV-1 actuated ATL cells.

79 ather moderate affinity of Indinavir against HTLV-1 PR and provides the basis for further structure-g

80 ortant aspects of the human response against HTLV-1 and could be an important tool for the developmen

81 e evaluated as privileged structures against HTLV-1 protease (HTLV-1 PR).

82 t be useful for developing a vaccine against HTLV-1.

83 raction of the brain stem was reduced in all HTLV-1-infected patients compared with controls (P < 0.0

84 We found that stable expression of an HTLV-1 accessory protein, HTLV-1 bZIP factor (HBZ), in J

85 Here we report an HTLV-1 recombinant virus among infected individuals in N

86 We show that an HTLV-1-infected cell line (MT-2) and naturally infected

87 ave used cryo-electron tomography to analyze HTLV-1 particle morphology.

88 have shown for the first time that HIV-1 and HTLV-1 Gag domains outside the CA (e.g., matrix and nucl

89 cal agent of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesi

90 Associations between specific diseases and HTLV-1 status were determined using logistic regression,

91 prevalent in endemic clusters globally, and HTLV-1 infects at least 5 to 10 million individuals.

92 Iatrogenic transmission of HCV and HTLV-1 occurred in mid-20th century Kinshasa, at the sam

93 B'-PP2A and HTLV-1 IN display nuclear co-localization, and the B' su

94 ty of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/SCID/gamma(C) (-/-) c-ki

95 assay was evaluated and did not detect anti-HTLV-1/2 IgG in 14% (5/36) of OF specimens from seroposi

96 A was developed and validated to detect anti-HTLV-1/2 IgG in OF.

97 drug target for the discovery of novel anti-HTLV-1 drugs.

98 an T-cell leukemia virus (HTLV; now known as HTLV-1) produced by a T-cell line from a lymphoma patien

99 s similarities to human retroviruses such as HTLV-1, the development of an effective treatment would

100 ommunity recruitment and blinded assessment, HTLV-1 infection was strongly associated with pulmonary

101 e receptor expression did not differ between HTLV-1-infected and uninfected individuals.

102 No associations were found between HTLV-1 and any assessed clinical condition among childre

103 eukemia (ATL), a T-cell malignancy caused by HTLV-1 infection.

104 malignant or inflammatory diseases caused by HTLV-1.

105 coinfection by HTLV-1 is associated with shorter survival for adults an

106 vent the senescence and G1 arrest induced by HTLV-1 Tax and vFLIP, respectively.

107 We matched 149 patients co-infected by HTLV-1 (cases) by age at HIV diagnosis and gender to equ

108 rm that hunters in Africa can be infected by HTLV-1 that is closely related to the strains circulatin

109 ice) were highly susceptible to infection by HTLV-1(WT), with a syndrome characterized by the rapid p

110 rt the notion that infection of monocytes by HTLV-1 is likely a requisite for viral persistence in hu

111 ATL is preceded by decades of chronic HTLV-1 infection, and the tumors carry both somatic muta

112 ishes the infectivity of the molecular clone HTLV-1(p12KO) In rabbits, HTLV-1(p12KO) is infective and

113 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

114 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

115 We detected HTLV-1 DNA in all three monocyte subsets and found that

116 mia (ATL)-like leukemic symptoms and display HTLV-1-specific adaptive immune responses.

117 As a first step in designing an effective HTLV-1 vaccine, we defined the CD8(+) and CD4(+) T cell

118 st defense responses, which may help explain HTLV-1-related pathogenesis and oncogenesis.

119 The MT-4 human T-cell line expresses HTLV-1 Tax and is permissive for replication of an HIV-1

120 Higher cerebrospinal fluid HTLV-1 proviral load (p = 0.01) was associated with thin

121 Blood was drawn for HTLV-1 serology and proviral load (PVL).

122 Different genotypes exist for HTLV-1: Genotypes b and d to g are restricted to central

123 The risk factors for HTLV-1 acquisition in humans via the interspecies transm

124 Risk factors for HTLV-1 seropositivity included intravenous injections at

125 mice may provide a window of opportunity for HTLV-1 replication and the selection of viral variants w

126 PCR was carried out for HTLV-1 provirus on buffy-coat DNAs.

127 s have been described, such a regulation for HTLV-1 has not been reported.

128 The use of OF serological screening for HTLV-1/2 infection could facilitate large-scale seroprev

129 s) are among the first potential targets for HTLV-1.

130 There is no effective treatment for HTLV-1, and the osteolytic mechanisms are not fully unde

131 e development of a therapeutic treatment for HTLV-1-mediated disease.

132 Free HTLV-1 virions are poorly infectious, so infection of T

133 e for Human Retrovirology (n = 131) and from HTLV-1/2-uninfected individuals (n = 64).

134 he antisense transcript-encoded protein from HTLV-1, is now well recognized as a potential factor for

135 ore, we observed that exosomes released from HTLV-1-infected Tax-expressing cells contributed to enha

136 All three monocyte subsets sorted from HTLV-1-infected individuals were positive for viral DNA,

137 fs of five retroviruses of different genera: HTLV-1, HIV-1, murine leukaemia virus (MLV), avian sarco

138 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus type 1) is a chroni

139 racteristics of individuals with low or high HTLV-1 proviral load (pVL), symptomatic disease, and the

140 ed to survival time in a large cohort of HIV-HTLV-1 co-infected and HIV mono-infected patients on cAR

141 with survival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on co

142 ins provide a better understanding about how HTLV-1 infection is associated with disease and HTLV-2 i

143 these functional differences may affect how HTLV-1 causes disease but HTLV-2 generally does not.

144 Human T-cell lymphotropic virus type I (HTLV-1) is an oncogenic retrovirus considered to be the

145 The human T-cell lymphotropic virus type I (HTLV-1) Tax transactivator initiates transformation in a

146 a defined capsid core, which likely impacts HTLV-1 particle infectivity.

147 ion of TrkB signaling increases apoptosis in HTLV-1-infected T cells and reduces phosphorylation of g

148 ing factor for dysregulation of autophagy in HTLV-1-transformed T cells and Tax-immortalized CD4 memo

149 this effect, BDNF expression is elevated in HTLV-1-infected T-cell lines compared to uninfected T ce

150 Among several regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene

151 CX3CR1 in classical monocytes were higher in HTLV-1-infected individuals than uninfected individuals;

152 Expression of TrkB is also higher in HTLV-1-infected T-cell lines than in uninfected T cells.

153 However, in HTLV-1-infected T cells, knockdown of HBZ expression did

154 assical patrolling monocytes is increased in HTLV-1-infected individuals, and they have increased exp

155 F/TrkB autocrine/paracrine signaling loop in HTLV-1-infected T cells that enhances the survival of th

156 w is that infectious spread is negligible in HTLV-1 persistence beyond early infection.

157 hting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

158 hat, albeit rare, recombination can occur in HTLV-1 and may play a role in the evolution of this retr

159 demonstrate the presence of recombinants in HTLV-1.

160 nflammation in the spinal cord, resulting in HTLV-1-associated myelopathy/tropical spastic paraparesi

161 ng that miR-28 may play an important role in HTLV-1 transmission.

162 ell-to-cell transmission, a critical step in HTLV-1 transmission and pathogenesis.

163 -mediated inflammatory conditions, including HTLV-1-associated myelopathy/tropical spastic paraparesi

164 kat cells (used as effector cells) increases HTLV-1 infection.

165 s have important implications for infectious HTLV-1 spread, particularly in the context of cell-to-ce

166 this study, we found that miR-28-3p inhibits HTLV-1 virus expression and its replication by targeting

167 ata provide further mechanistic insight into HTLV-1-mediated subversion of cellular host defense resp

168 nsfected with Rex-wild-type and Rex-knockout HTLV-1 molecular clones using splice site-specific quant

169 Despite low prevalence, many HTLV-1-infected patients who do not fulfill criteria for

170 tated in ATL than did high-risk, age-matched HTLV-1 carriers who remained ATL-free after a median of

171 ntegral component of the intasome to mediate HTLV-1 integration.

172 Many of the ~20 million HTLV-1 infected people will develop severe leukaemia or

173 Moreover, HTLV-1 infection was linked to bite severity.

174 and we estimate that between 100 and 200 new HTLV-1 clones are created and killed every day.

175 protective role of miR-28-3p against de novo HTLV-1 infection.

176 at Gag proteins with a chimeric HIV-1 CA NTD/HTLV-1 CA CTD did not result in Gag oligomerization rega

177 ent high-throughput data on the abundance of HTLV-1 clones, and recent estimates of HTLV-1 clonal div

178 the differences in transforming activity of HTLV-1 and -2.

179 tropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tropical spastic paraparesi

180 Analysis of HTLV-1 integrations in two cell lines, HuT 102 and MJ, i

181 lassical monocytes was lower in the blood of HTLV-1-infected individuals than in that of uninfected i

182 The brains of HTLV-1-infected patients, with and without HAM but no cl

183 controls [HCs], 17 asymptomatic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS

184 g its expression within a molecular clone of HTLV-1.

185 Functional comparisons of HTLV-1 and HTLV-2 proteins provide a better understandin

186 gy to deregulate autophagy in the context of HTLV-1 transformation of T cells.

187 ce of HTLV-1 clones, and recent estimates of HTLV-1 clonal diversity that are substantially higher th

188 to examine in depth the molecular events of HTLV-1 replication and the mechanisms of action of viral

189 ance, confirming the polyclonal expansion of HTLV-1-infected cells in vivo HTLV-1(p12KO) infection in

190 significant increase in clonal expansion of HTLV-1-infected lymphocytes in coinfected asymptomatic i

191 CD4:CD8 ratio inflation is a feature of HTLV-1 infection, whereas enhanced CD4+ T cell maturatio

192 ase class III resulted in impaired growth of HTLV-1-transformed T cells, indicating a critical role o

193 Given the low incidence of HTLV-1-associated diseases among carriers, such cellular

194 igh prevalence might reduce the incidence of HTLV-1-induced disease.

195 evidence that the known poor infectivity of HTLV-1 particles may correlate with HTLV-1 particle popu

196 ge, the most potent nonpeptidic inhibitor of HTLV-1 PR described so far.

197 hich significantly revisits our knowledge of HTLV-1 pathogenesis and other NF-kappaB-related diseases

198 osure and was associated with high levels of HTLV-1 DNA in blood and the expansion of CD4(+) CD25(+)

199 er with prior findings in a macaque model of HTLV-1 infection, support the notion that infection of m

200 unately, there are very few animal models of HTLV-1 infection useful for testing vaccine approaches.

201 A number of HTLV-1 subtypes have been described in different populat

202 ich in turn is correlated with the number of HTLV-1-infected clones, which are created by de novo inf

203 s in the natural history and pathogenesis of HTLV-1 infection.

204 se humanized mice mirrors the early phase of HTLV-1 infection in humans, providing a useful model to

205 Thus, the process of HTLV-1 cell-to-cell transmission within the host helps i

206 bjective measures of gait, quantification of HTLV-1 proviral load in peripheral blood mononuclear cel

207 YY1 binds to the R region of HTLV-1 RNA in vitro and in vivo, leading to increased tr

208 The risk of HTLV-1-associated malignancy and inflammatory disease is

209 ideal for further examination of the role of HTLV-1 Tax in osteolytic tumor formation and the develop

210 Therefore, infectious spread of HTLV-1 within the T-cell population may be one underlyin

211 In the first study of HTLV-1 disease associations based on community recruitme

212 ammatory myelopathy occurring in a subset of HTLV-1-infected individuals.

213 rge-scale, community-based, health survey of HTLV-1 and its disease associations in this setting.

214 ppaB activation by the viral oncogene Tax of HTLV-1.

215 The p9 localization is similar to that of HTLV-1 p12 and induced a strong decrease in the calretic

216 icate that YY1 is a potent transactivator of HTLV-1 gene expression acting via binding viral RNA, rat

217 acts also facilitate DC-mediated transfer of HTLV-1 to autologous CD4(+) T cells.

218 We hypothesized that transformation of HTLV-1-infected CCR4+ T cells into Th1-like cells plays

219 us Australian populations, but its impact on HTLV-1 has not been described.

220 s can be used to quantify and study HIV-1 or HTLV-1 cell-mediated infection in a simple one-step tran

221 Here we demonstrate that ATL-derived or HTLV-1-transformed cells are dependent on continuous Tax

222 ia/lymphoma and tropical spastic paraparesis/HTLV-1-associated myelopathy in about 5% of infected ind

223 Clones of premalignant HTLV-1-infected cells bearing known driver mutations wer

224 The ease with which chronic and productive HTLV-1 infection can be established in cell culture thro

225 HTLV-1 protease (HTLV-1 PR) is an aspartic protease which represents a pr

226 ivileged structures against HTLV-1 protease (HTLV-1 PR).

227 Here we found that the viral protein HTLV-1 bZIP factor (HBZ) promotes infectivity.

228 e expression of an HTLV-1 accessory protein, HTLV-1 bZIP factor (HBZ), in Jurkat T cells increases ho

229 ic processes, fitted to previously published HTLV-1 clonal diversity estimates.

230 he molecular clone HTLV-1(p12KO) In rabbits, HTLV-1(p12KO) is infective and persists efficiently.

231 xpression, while YY1 down-regulation reduces HTLV-1 expression.

232 The human-pathogenic retroviruses HTLV-1 and HIV-1 can be transmitted more efficiently in

233 ma specimens were obtained from seropositive HTLV-1/2-infected patients attending the National Centre

234 The 2 groups had a similar HTLV-1 proviral load, but there was a significant increa

235 ling the expression of alternatively spliced HTLV-1 mRNAs and suggest a link between the cycling prop

236 of the complete set of alternatively spliced HTLV-1 mRNAs.

237 r B' incapable of binding to and stimulating HTLV-1 and -2 IN strand transfer activity.

238 ory mechanism may be important for long-term HTLV-1 infection.

239 We conclude that HTLV-1/HBV coinfection may predispose to HTLV-1-associat

240 Our results demonstrate that HTLV-1 Gag is capable of membrane targeting and particle

241 sion electron microscopy to demonstrate that HTLV-1 particles produced from a distinct chronically in

242 Previously, our group found that HTLV-1 HBZ and HTLV-2 APH-2 had distinct effects in vivo

243 In addition, we found that HTLV-1, subtype 1A isolates corresponding to the Japanes

244 We show here that HTLV-1 may be able to successfully infect the T cells an

245 Importantly, we revealed that HTLV-1 bZIP factor (HBZ) protein which is expressed in a

246 These data show that HTLV-1-infected T-cell clones carrying key oncogenic dri

247 The HTLV-1 and HTLV-2 prevalences among US blood donors has

248 The HTLV-1 particle structure is still poorly understood, an

249 The HTLV-1 R sequence alone is sufficient to provide YY1 res

250 All the HTLV-1-positive hunters bitten by a gorilla or chimpanze

251 Mice expressing the HTLV-1 oncogene Tax, driven by the human granzyme B prom

252 antisense strand of its proviral genome, the HTLV-1 basic leucine zipper factor (HBZ), which inhibits

253 respectively, which, in contrast to HBZ, the HTLV-1 homologue, do not contain a typical bZIP domain.

254 t mapped not to YY1 DNA-binding sites in the HTLV-1 LTR but to the R region.

255 Indeed, the HTLV-1 strains currently present in North Africa have or

256 To more clearly define the roles of the HTLV-1 CA amino-terminal domain (NTD) and CA CTD in part

257 articles, highlighting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

258 ing experimental system for the study of the HTLV-1 particle structure.

259 critical infection-related functions of the HTLV-1 regulatory protein Tax.

260 CTD, but the HIV-1 CA NTD cannot replace the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains

261 In this study, the HTLV-1 capsid amino-terminal domain was found to provide

262 e constitute a useful model for studying the HTLV-1-associated polyclonal proliferation of CD4(+) T c

263 observations support the conclusion that the HTLV-1 CA NTD can functionally replace the HIV-1 CA CTD,

264 place the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains provide distinct contributions to G

265 In this study, we found that the HTLV-1-encoded protein HBZ activates expression of BDNF,

266 se cryo-electron microscopy to visualize the HTLV-1 intasome at 3.7- angstrom resolution.

267 Furthermore, chimeric Gag proteins with the HTLV-1 CA NTD produced particles phenotypically similar

268 inical examination by a physician blinded to HTLV-1 status, clinical records and spirometry results.

269 y structures of two representatives bound to HTLV-1 PR were determined, and the structural basis of t

270 rall results suggest that HBZ contributes to HTLV-1 infectivity.IMPORTANCE Human T-cell leukemia viru

271 lia, and report on 53 individuals exposed to HTLV-1 with no transmissions documented (95% confidence

272 hat HTLV-1/HBV coinfection may predispose to HTLV-1-associated malignant disease.

273 type 1 (STLV-1), a virus closely related to HTLV-1, in olive baboons (Papio anubis).

274 d in resting T cells, which are resistant to HTLV-1 infection, we investigated a potential protective

275 ttributed to the cellular immune response to HTLV-1-infected lymphocytes.

276 produced particles phenotypically similar to HTLV-1 immature particles, highlighting the importance o

277 ase in the calreticulin signal, similarly to HTLV-1 p12.

278 ibutions of infectious and mitotic spread to HTLV-1 persistence are unknown, and will determine the e

279 uninfected target T cells and then transfer HTLV-1 virus particles to the target cells.

280 and Env proteins persistently; and transmit HTLV-1 to naive HOS, SupT1, and Jurkat T reporter cell l

281 In arsenic/interferon-treated HTLV-1 transformed or ATL cells, Tax is recruited onto N

282 to assess the infectivity of both wild-type HTLV-1 (HTLV-1(WT)) and HTLV-1(p12KO) We found that NOD/

283 s (HCV) and human T-cell lymphotropic virus (HTLV-1) can be used to investigate past iatrogenic trans

284 re infected with human T lymphotropic virus (HTLV-1).

285 l expansion of HTLV-1-infected cells in vivo HTLV-1(p12KO) infection in a bone marrow-liver-thymus (B

286 25.9%) were HCV seropositive; 26 (3.1%) were HTLV-1-seropositive.

287 A vaccine is urgently needed in areas where HTLV-1 is endemic.

288 These data suggest a model whereby HTLV-1 infection augments the number of classical monocy

289 rmalities were more common among adults with HTLV-1 infection.

290 We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis and sex, to an eq

291 ivity of HTLV-1 particles may correlate with HTLV-1 particle populations containing few virus particl

292 2 groups of Indigenous adults infected with HTLV-1, either alone or coinfected with HBV.

293 hocytic cell lines chronically infected with HTLV-1, particularly the MT-2 cell line, which harbors t

294 ysregulation of CD4(+) T cells infected with HTLV-1.

295 lops in 2 to 5% of individuals infected with HTLV-1.

296 FACT proteins also interfere with HTLV-1 Tax-LTR-mediated transcription and viral latency,

297 naive CD4+ T cells correlated inversely with HTLV-1 pVL (rs = -0.344, P = .026).

298 unosuppressive therapy, 38 women living with HTLV-1 infection, at a median age of 59 (52-68) years, w

299 y of an asymptomatic carrier or patient with HTLV-1-associated myelopathy/tropical spastic paraparesi

300 ion and disease progression in patients with HTLV-1-associated inflammatory diseases.